Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Jan 28

PMID 24463293

Citations 34

Authors

Robert D Wyse

Gary L Dunbar

Julien Rossignol

Affiliations

Soon will be listed here.

Abstract

The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson's, Alzheimer's and Huntington's diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.

Citing Articles

Subcutaneous delivery of mesenchymal stromal cells induces immunoregulatory effects in the lymph node prior to their apoptosis.

Zheng D, Bhuvan T, Payne N, Pang S, Mendonca S, Hutchinson M Stem Cell Res Ther. 2024; 15(1):432.

PMID: 39551813 PMC: 11572146. DOI: 10.1186/s13287-024-04060-0.

Selected Interleukins Relevant to Multiple Sclerosis: New Directions, Potential Targets and Therapeutic Perspectives.

Mado H, Stasiniewicz A, Adamczyk-Sowa M, Sowa P Int J Mol Sci. 2024; 25(20).

PMID: 39456713 PMC: 11506881. DOI: 10.3390/ijms252010931.

Therapeutic Applications of Engineered Mesenchymal Stromal Cells for Enhanced Angiogenesis in Cardiac and Cerebral Ischemia.

Hegde M, Singh A, Kannan S, Kolkundkar U, Seetharam R Stem Cell Rev Rep. 2024; 20(8):2138-2154.

PMID: 39305405 PMC: 11554727. DOI: 10.1007/s12015-024-10787-3.

Cellular Localization and Distribution of TGF-β1, GDNF and PDGF-BB in the Adult Primate Central Nervous System.

Li H, Dan Q, Chen Y, Chen L, Zhang H, Mu D Neurochem Res. 2023; 48(8):2406-2423.

PMID: 36976393 DOI: 10.1007/s11064-023-03909-9.

Transplantation of human adipose-derived stem cells overexpressing LIF/IFN-β promotes recovery in experimental autoimmune encephalomyelitis (EAE).

Yousefi M, Nabipour A, Ganjalikhani Hakemi M, Ashja-Arvan M, Amirpour N, Salehi H Sci Rep. 2022; 12(1):17835.

PMID: 36284106 PMC: 9596436. DOI: 10.1038/s41598-022-21850-9.

References

Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I . Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect. 1992; 4(1):79-95. DOI: 10.1007/BF02257624. View

Clary D, Reichardt L, Gage F . TrkA activation is sufficient to rescue axotomized cholinergic neurons. Neuron. 1996; 16(3):653-63. PMC: 2757416. DOI: 10.1016/s0896-6273(00)80084-7. View

Lopez-Verrilli M, Court F . Exosomes: mediators of communication in eukaryotes. Biol Res. 2013; 46(1):5-11. DOI: 10.4067/S0716-97602013000100001. View

Deak E, Seifried E, Henschler R . Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol. 2010; 29(5):514-29. DOI: 10.3109/08830185.2010.498931. View

Deng W, Fu M, Cao Y, Cao X, Wang M, Yang Y . Angelica sinensis polysaccharide nanoparticles as novel non-viral carriers for gene delivery to mesenchymal stem cells. Nanomedicine. 2013; 9(8):1181-91. DOI: 10.1016/j.nano.2013.05.008. View

Grondin R, Kaytor M, Ai Y, Nelson P, Thakker D, Heisel J . Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012; 135(Pt 4):1197-209. PMC: 3326247. DOI: 10.1093/brain/awr333. View

Liu L, Eckert M, Riazifar H, Kang D, Agalliu D, Zhao W . From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier?. Stem Cells Int. 2013; 2013:435093. PMC: 3753739. DOI: 10.1155/2013/435093. View

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

Glavaski-Joksimovic A, Bohn M . Mesenchymal stem cells and neuroregeneration in Parkinson's disease. Exp Neurol. 2013; 247:25-38. DOI: 10.1016/j.expneurol.2013.03.016. View

10.

Philippe B, Luc S, Valerie P, Jerome R, Alessandra B, Louis C . Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials. Stem Cells Int. 2010; 2010:503593. PMC: 2968415. DOI: 10.4061/2010/503593. View

11.

Finkbeiner S, Mitra S . The ubiquitin-proteasome pathway in Huntington's disease. ScientificWorldJournal. 2008; 8:421-33. PMC: 2637619. DOI: 10.1100/tsw.2008.60. View

12.

Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B . Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(5):246-57. DOI: 10.1159/000017069. View

13.

Gunjima K, Tomiyama R, Takakura K, Yamada T, Hashida K, Nakamura Y . 3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway. J Cell Biochem. 2013; 115(1):151-60. DOI: 10.1002/jcb.24643. View

14.

Weissmiller A, Wu C . Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012; 1(1):14. PMC: 3542569. DOI: 10.1186/2047-9158-1-14. View

15.

Kinoshita Y, Kamitani H, Mamun M, Wasita B, Kazuki Y, Hiratsuka M . A gene delivery system with a human artificial chromosome vector based on migration of mesenchymal stem cells towards human glioblastoma HTB14 cells. Neurol Res. 2009; 32(4):429-37. DOI: 10.1179/174313209X455718. View

16.

Mizuno K, Carnahan J, Nawa H . Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol. 1994; 165(1):243-56. DOI: 10.1006/dbio.1994.1250. View

17.

Durbec P, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D . GDNF signalling through the Ret receptor tyrosine kinase. Nature. 1996; 381(6585):789-93. DOI: 10.1038/381789a0. View

18.

Reiner A, Albin R, Anderson K, DAMATO C, Penney J, Young A . Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988; 85(15):5733-7. PMC: 281835. DOI: 10.1073/pnas.85.15.5733. View

19.

Dwivedi P, Anderson P, Powell B . Development of an efficient, non-viral transfection method for studying gene function and bone growth in human primary cranial suture mesenchymal cells reveals that the cells respond to BMP2 and BMP3. BMC Biotechnol. 2012; 12:45. PMC: 3431223. DOI: 10.1186/1472-6750-12-45. View

20.

Canals J, Pineda J, Torres-Peraza J, Bosch M, Martin-Ibanez R, Teresa Munoz M . Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004; 24(35):7727-39. PMC: 6729627. DOI: 10.1523/JNEUROSCI.1197-04.2004. View